Market Overview

Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug

Share:
Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug
Related LJPC
The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist
The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
Recent Analysis Shows Professional Diversity Network, Quanex Building Products, HTG Molecular ... (GuruFocus)

In the absence of a potential buyout, the downside risk for La Jolla Pharmaceutical Company (NASDAQ: LJPC) is greater than the upside potential in the next two to three years, according to Jefferies. 

The Analyst

Jefferies analyst Eun Yang downgraded La Jolla from Buy to Underperform and lowered the price target from $40 to $29, suggesting 21-percent downside from current levels.

The Thesis

Polls with critical care physicians and pharmacy and therapeutics committee members showed only a modest sales opportunity for Giapreza, La Jolla's drug for low blood pressure, Yang said in a Monday note.

The Giapreza poll results point to 20- and 30-percent penetration of Giapreza in 2L and 3L, respectively, translating to a peak U.S. sales estimates of $324 million versus a prior estimate of $535 million, according to Jefferies.

The difference is due to lower transaction cost — $4,500 rather than the previous $8,000 — and a slightly higher number of patients. 

La Jolla shares have gained 15 percent year-to-date compared to a 1-percent drop for the Nasdaq Biotechnology Index.

In December, HC Wainwright initiated coverage of La Jolla with a Buy rating and a $62 price target, citing a Feb. 28 PDUFA date for LJPC-501, a treatment candidate for vasodilatory shock.

The Price Action

La Jolla shares are up about 90 percent over the past year.

Shares were sliding more than 7 percent percent to $34.21 Monday morning. 

Related Links:

19 Biotech Stocks With Clinical Trial Outcomes In February

Attention Biotech Investors: February PDUFA Catalysts Come Calling

Latest Ratings for LJPC

DateFirmActionFromTo
Aug 2018JP MorganMaintainsUnderweightUnderweight
Aug 2018JefferiesMaintainsUnderperformUnderperform
Feb 2018JefferiesDowngradesBuyUnderperform

View More Analyst Ratings for LJPC
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (LJPC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NKEOppenheimerUpgrades0.0
SBEvercore ISI GroupUpgrades4.5
PTIRBC CapitalUpgrades0.0
GPSJP MorganDowngrades24.0
GIIIB. Riley FBRUpgrades47.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

New Legal Wars: How A Few Proposed Bills Can Shape The Gambling Industry In 2018 And Beyond

Should Value Investors Be Taking A Look At Energizer Holdings?